Close Menu

Agendia

The US DOJ alleged that the company conspired to "artificially delay" ordering its MammaPrint test in order to circumvent Medicare's 14-day rule.

At the American Society of Clinical Oncology's virtual meeting, investigators presented two new studies of BluePrint classification patterns.

News items for the in vitro diagnostics industry for the week of Dec. 30, 2019

MammaPrint classifies patients as either high risk or low risk of recurrence over a 10-year period while BluePrint classifies patients by breast cancer subtype.

Laboratory Corporation of American said this week that its Covance Drug Development segment will buy Envigo's nonclinical research services business, while Envigo's Research Models Services business will buy LabCorp's Covance Research Products business in a $485 million deal to be paid by LabCorp.

The group recommends Myriad Genetics' EndoPredict, NanoString's Prosigna, and Genomic Health's Oncotype DX tests for guiding chemotherapy decisions if certain conditions are met.

At the conference, researchers presented data from a number of studies using molecular diagnostic tools to better characterize breast cancer recurrence and treatment outcomes.

In the I-SPY 2 trial, investigators analyzed whether MammaPrint scores and BluePrint subtypes could help identify patients who would respond better to treatments.

The new additions reflect data published this summer in the TAILORx trial, which speak to the chemopredictive ability of Genomic Health's Oncotype DX.

Under the terms of the deal, Beijing-based GeneCast has the exclusive right to market Agendia's MammaPrint and BluePrint tests to Chinese customers.

Pages